NANOMEDICINE IN CANCER THERAPY: FROM BENCH TO BEDSIDE

Abstract

Cancer remains one of the most pressing global health challenges, characterized by high mortality rates, treatment resistance, and adverse side effects from conventional therapies. Traditional approaches such as chemotherapy, radiotherapy, and surgery often suffer from limitations including nonspecific drug distribution, systemic toxicity, and poor efficacy in advanced or metastatic cancers. In response to these challenges, nanomedicine has emerged as a transformative strategy that applies nanoscale engineering to design precise, minimally invasive, and highly effective therapeutic systems.This study investigates the role of engineered nanoparticles—such as liposomes, dendrimers, polymeric carriers, and micelles—in enhancing drug delivery, bioavailability, and therapeutic targeting for cancer treatment. A comprehensive methodology was employed to evaluate nanoparticle formulations using in silico simulations and in vitro dataset analysis, focusing on drug encapsulation efficiency, tumor accumulation rates, controlled drug release kinetics, and therapeutic index. Various targeting mechanisms, including passive (via enhanced permeability and retention effect) and active (ligand-receptor mediated), were assessed for their impact on cellular uptake and treatment precision.The results revealed that functionalized nanoparticles achieved significantly higher tumor-specific accumulation and prolonged systemic circulation while reducing cytotoxic effects on healthy cells. Stimuli-responsive nanocarriers demonstrated effective pH-triggered and enzymatic drug release in tumor microenvironments, improving treatment specificity. Multifunctional systems integrating therapeutic and diagnostic capabilities enabled real-time monitoring and dynamic adjustment of treatment regimens.In conclusion, nanomedicine offers a promising pathway toward personalized and precision oncology by overcoming the fundamental limitations of conventional cancer therapies. Its ability to deliver targeted, controlled, and adaptive treatments holds potential to improve clinical outcomes, reduce side effects, and enhance patient quality of life. Continued research, regulatory advancement, and clinical translation of nanoparticle-based systems are essential to fully realize their transformative impact on cancer care in the era of precision medicine.